A detailed history of Parallel Advisors, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 59 shares of RCKT stock, worth $693. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59
Holding current value
$693
% of portfolio
0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$17.6 - $25.88 $1,038 - $1,526
59 New
59 $1,000
Q2 2022

Aug 01, 2022

SELL
$7.96 - $16.64 $2,332 - $4,875
-293 Closed
0 $0
Q1 2022

Apr 28, 2022

BUY
$13.16 - $23.68 $3,855 - $6,938
293 New
293 $5,000
Q4 2021

Jan 20, 2022

SELL
$21.52 - $36.02 $2,001 - $3,349
-93 Closed
0 $0
Q3 2021

Nov 02, 2021

SELL
$27.42 - $48.97 $1,371 - $2,448
-50 Reduced 34.97%
93 $3,000
Q2 2021

Aug 06, 2021

BUY
$39.41 - $47.25 $5,044 - $6,048
128 Added 853.33%
143 $6,000
Q1 2021

Apr 23, 2021

BUY
$43.34 - $65.91 $650 - $988
15 New
15 $1,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $890M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.